Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dacarbazine and Carmustine in Metastatic Melanoma
NCT01692691 · Western Regional Medical Center · PHASE2 · terminated · last registry update 2018-04-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI decision” | – | Registry record, Western Regional Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF3R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-12-10Results posted on the registry: Children's Oncology Group, Asparaginase + Cyclophosphamide (NCT00557193)
- 2018-10-24Results posted on the registry: Children's Oncology Group, Carboplatin + Cisplatin (NCT00336024)
- 2018-04-17Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Paclitaxel (NCT03498716)
- 2018-04-11Phase 3 first posted: Hoffmann-La Roche, Cyclophosphamide + Doxorubicin (NCT03493854)
- 2018-03-29Phase 3 first posted: Dartmouth-Hitchcock Medical Center, Cyclophosphamide + Fludarabine (NCT03480360)
- 2018-03-26Phase 3 first posted: Haukeland University Hospital, Cyclophosphamide and ATG + Alemtuzumab (NCT03477500)
- 2017-08-29Results posted on the registry: AstraZeneca, Selumetinib + Docetaxel (NCT01933932)
- 2017-08-15Phase 3 first posted: Arog Pharmaceuticals, Inc., Crenolanib + Cytarabine (NCT03250338)
- 2017-08-11Phase 3 first posted: BioLineRx, Ltd., BL-8040 1.25 mg/kg + G-CSF + Placebo +G-CSF (NCT03246529)
- 2017-08-09Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Cabazitaxel + Neulasta (NCT01437488)
- 2017-07-14Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Docetaxel (NCT01012297)
- 2017-06-09Phase 3 first posted: Astellas Pharma Inc, Gilteritinib + Cytarabine (NCT03182244)
- 2017-05-12Results posted on the registry: Children's Oncology Group, vincristine sulfate + prednisone (NCT00381680)
- 2017-04-26Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Cytarabine (NCT00792948)
- 2017-04-17Results posted on the registry: SWOG Cancer Research Network, pegfilgrastim + AC regimen (NCT00070564)
- 2017-04-06Phase 3 first posted: BeyondSpring Pharmaceuticals Inc., Plinabulin + Pegfilgrastim (NCT03102606)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision